Titan Medical today announced another amending agreement in its amalgamation agreement with Conavi Medical.

Titan Medical今天宣布了其与Conavi Medical的合并协议中的另一项修订协议。

In March, the companies entered into a definitive amalgamation agreement to combine in an all-stock transaction. They aim to commercialize Conavi’s Novasight Hybrid system for guiding common minimally invasive coronary procedures. The companies offered another update in April saying that the deal continued to progress..

3月，两家公司签订了最终合并协议，以进行全股票交易。他们的目标是将Conavi的Novasight混合系统商业化，以指导常见的微创冠状动脉手术。这些公司在4月份提供了另一份最新消息，称交易仍在继续进行。。

Dated Aug. 13, the amending agreement alters certain closing conditions. Alterations included extending the outside date for completion of the proposed transaction to Oct. 10, 2024. The amendment also extends the date by which a concurrent financing must be committed to Sept. 3, 2024.

8月13日，修订协议改变了某些交割条件。变更包括将拟议交易的外部完成日期延长至2024年10月10日。该修正案还将同时融资的承诺日期延长至2024年9月3日。

Titan said the companies agreed to reduce the minimum aggregate size of that financing from $15 million to $7.5 million. They also extended the date by which Conavi must complete financial statements to Aug. 23, 2024. Additionally, the agreement reduces the minimum net cash Titan must have at the effective time from $5 million to $2 million..

Titan表示，两家公司同意将融资的最低总规模从1500万美元降至750万美元。他们还将Conavi必须完成财务报表的日期延长至2024年8月23日。此外，该协议将泰坦在生效时必须拥有的最低净现金从500万美元降至200万美元。。

The companies also agreed to extend the target date for Titan’s annual general meeting of shareholders to on or before Sept. 30, 2024. Titan plans to schedule a date for the meeting “as soon as practicable,” according to a news release.

两家公司还同意将Titan年度股东大会的目标日期延长至2024年9月30日或之前。据一份新闻稿称，泰坦计划“尽快”安排会议日期。

According to the companies, the amending agreement also makes certain technical and mechanical amendments. Among other things, these changes provide for the conversion of Conavi preferred shares into Conavi common shares and the consolidation of Conavi shares immediately prior to the effective time of the amalgamation..

据这些公司称，修订协议还对技术和机械进行了某些修改。除其他事项外，这些变更规定将科纳维优先股转换为科纳维普通股，并在合并生效之前立即合并科纳维股份。。

Background on the Titan Medical – Conavi deal

Titan Medical–Conavi交易的背景

This merger comes after more than a year of uncertainty around the future at Titan Medical. In late 2022, Titan suspended a special meeting of shareholders meant to vote on a share consolidation plan. Management decided to begin a strategic review, and announced significant cost-cutting measures.

在泰坦医疗公司（TitanMedical）未来一年多的不确定性之后，进行了此次合并。2022年末，泰坦公司暂停了一次旨在对股票合并计划进行表决的股东特别会议。管理层决定开始战略审查，并宣布了重大的成本削减措施。

Titan went on to halt development of its ENOS surgical robot in February 2023. The company began selling assets and licensed its IP to avoid insolvency. It eventually licensed its surgical robotics IP to market leader Intuitive Surgical.

2023年2月，Titan停止了ENOS手术机器人的开发。该公司开始出售资产并许可其知识产权以避免破产。它最终将其手术机器人IP授权给市场领导者直觉手术。

The two companies aim to commercialize Conavi’s Novasight Hybrid system for guiding common minimally invasive coronary procedures.

这两家公司的目标是将Conavi的Novasight混合系统商业化，以指导常见的微创冠状动脉手术。

Conavi Medical designs, manufactures and markets imaging technologies for guiding minimally invasive cardiovascular procedures. Novasight Hybrid combines both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries..

Conavi Medical设计、制造和销售用于指导微创心血管手术的成像技术。Novasight Hybrid结合了血管内超声（IVUS）和光学相干断层扫描（OCT），可以同时对冠状动脉进行共同注册成像。。

Novasight Hybrid has FDA 510(k) clearance and regulatory nods in other geographies like Canada, China and Japan. With Titan Medical, Conavi expects the combined company to become a commercial-stage leader in hybrid intravascular imaging.

Novasight Hybrid在加拿大、中国和日本等其他地区拥有FDA 510（k）许可和监管点。凭借Titan Medical，Conavi预计合并后的公司将成为混合血管内成像的商业舞台领导者。